| |
|
Symposium Co-Chairs
Paul A. Bunn, Jr., MD
James Dudley Chair in Cancer Research
Professor, Medical Oncology
University of Colorado Denver
Aurora, CO
Executive Director, USA
International Association for the Study of Lung Cancer
(IASLC)
Roy S. Herbst, MD, PhD
Professor of Medicine
Chief of Medical Oncology
Associate Director for Translational Research
Yale Comprehensive Cancer Center
Smilow Cancer Hospital at Yale-New Haven
Yale School of Medicine
New Haven, CT
Corey J. Langer, MD
Professor of Medicine
Director, Thoracic Oncology
Division of Hematology-Oncology
Abramson Cancer Center
University of Pennsylvania
Philadelphia, PA
Vice Chair, Radiation Therapy Oncology Group
(RTOG)
Walter J. Curran, Jr., MD
Executive Director
Winship Cancer Institute of Emory University
Professor & Chairman
Department of Radiation Oncology
Group Chairman
Radiation Therapy Oncology Group (RTOG)
Edward B. Garon, MD
Associate Professor of Medicine
Department of Medicine, Hematology/Oncology
Jonsson Comprehensive Cancer Center
Thoracic Oncology Program Area
University of California at Los Angeles School of Medicine
Los Angeles, CA
Barbara J. Gitlitz, MD
Associate Professor of Clinical Medicine
Department of Medicine
USC Norris Comprehensive Cancer Center
Los Angeles, CA
Fred R. Hirsch, MD, PhD
Professor, Division of Medical Oncology
University of Denver School of Medicine
Denver, Colorado
John V. Heymach, MD, PhD
Professor of Thoracic Head/Neck Medical Oncology
Professor of Cancer Biology
The University of Texas M. D. Anderson Cancer Center
Houston, TX
Thomas J. Lynch, Jr., MD
Professor of Medicine
Director, Yale Cancer Center
Physician-in-Chief,
Smilow Cancer Hospital, Yale-New Haven
New Haven, CT
Philip C. Mack, PhD
Associate Adjunct Professor
Co-Leader Molecular Pharmacology
UC Davis Cancer Center
Sacramento, CA
Vincent A. Miller, MD
Associate Attending Physician
Thoracic Oncology Service
Memorial Sloan-Kettering Cancer Center
New York, NY
Suresh S. Ramalingam, MD
Director
Division of Medical Oncology
Associate Professor
Emory University School of Medicine
Atlanta, Georgia
Alan B. Sandler, MD
Professor of Medicine
Division Chief, Hematology & Medical Oncology
DeArmond Chair, Clinical Cancer Research
Oregon Health & Science University
Portland, OR
Joan H. Schiller, MD
Professor & Division Chief
Hematology-Oncology
Deputy Director, Harold C. Simmons Cancer Center
Andrea L. Simons Distinguished Chair in Cancer Research
UT Southwestern Medical Center
Dallas, TX
Chair, Lung Committee, Eastern Cooperative Oncology Group
(ECOG)
George R. Simon, MD, FACP, FCCP
Associate Professor of Medicine & Oncology
The Burtschy Family Endowed Chair in Cancer Research
Assistant Director, Clinical Investigations, Hollings Cancer Center
Division of Hematology/Oncology, Department of Medicine
Medical University of South Carolina
Charleston, SC
Mark A. Socinski, MD
Professor of Medicine and Thoracic Surgery
Director, Lung Cancer Section, Division of Hematology/Oncology
Co-Director, UPMC Lung Cancer Center of Excellence
Co-Director, Lung and Thoracic Malignancies Program
University of Pittsburgh
Pittsburgh, PA
|
|
|
|
CASE-BASED LEARNING
Renaissance Los Angeles Airport Hotel
9620 Airport Boulevard, Los Angeles, CA 90045
Saturday, September 17, 2011
Personalized medicine for treating lung cancer is a reality. This past year there has been much new "practice-changing" data published that affects the optimal way to treat, manage and care for your patients with lung cancer. This symposium will help you improve your selection of the most appropriate new therapeutic strategies, and will also help you to identify the patient sub-populations of breast cancer who will respond to personalized therapies.
Taught by the top academic experts and best teachers, this is THE symposium on lung cancer that you should attend in 2011. This is the fourth year of this symposium and it continues to attract a full room of lung cancer clinicians who leave the program with the expert knowledge and competence needed to improve patient outcomes.
|
|
|
|
Overview |
Back to Top |
|
The primary objective of the Fourth Annual Symposium on Personalized Therapies and Best Clinical Practices for Lung Cancer and its corresponding, on demand, Web-based Internet enduring materials is to provide oncologists, hematologist/oncologists and allied healthcare professionals treating lung cancer patients with the knowledge and competence enabling them to close several very important Practice Gaps arising primarily from important data presented at the annual ASCO meeting in June 2010 and information identified from other sources, especially direct measurements: interviews and focus groups with clinicians treating lung cancer. This information will help enable clinicians to treat their patients with the optimal personalized approaches in order to improve patient outcomes and minimize drug-induced toxicities. This data will be supplemented, as needed, with additional data from the June 2011 ASCO meeting and from the other major meetings in 2011, including the 14th World Lung Cancer Conference in Amsterdam in July 2011, as well as from publications, and other data sources and interviews with academic experts and community-based oncologists between now and September 17, 2011.
|
|
|
| Educational Statement of Need |
Back to Top |
|
The Biomedical Learning Institute (BMLI) has conducted a very extensive Practice Gap identification and Needs Assessment with the target audience of oncologists, hematologist/oncologists and allied healthcare professionals involved in the treatment, care and/or management of patients with lung cancer. The major Practice Gaps addressed in this activity are listed below.
- There is a practice gap between the community-based oncologists' knowledge and understanding of the new CAP/IASLC recommended guidelines for molecular biomarker tests and the roles of these tests in the NSCLC algorithm for therapy.
- There is a practice gap between the methodology used by academics and researchers and the methodology used in the community for devising treatment strategies for NSCLC patients across all lines of therapy.
- There is a practice gap between the fact that most community-based oncologists do not order the EGFR mutation tests before initial NSCLC therapy for the appropriate patients and the need to do this test almost routinely, at the very least for non-smokers or light smokers. This results in under treating mutation patients with the ideal therapy.
- The practice gap is that despite the FDA indication for pemetrexed for NSCLC patients with nonsquamous histology, and the warning against using bevacizumab for squamous histology, such critical histology testing is not being done routinely.
- There is a practice gap between what most community-based oncologists understand as to which drugs can be given safely at full doses to treat NSCLC and what the published literature reveals, especially with multi-targeted antifolate inhibition that is becoming an established gold standard for mutation-negative nonsquamous NSCLC.
- A practice gap exists because many community-based oncologists are not using regimens that inhibit angiogenesis where experts and clinical data support such usage as being the ideal practice.
- There is a practice gap between what community oncologists know and what academic oncologists know about treating EGFR-resistant NSCLC patients. The ideal, or more effective regimens or agents, including those adding to or replacing therapy solely targeting EGFR, are not being used by most community-based oncologists.
- There is a practice gap between what community oncologists do not know and what academic oncologists do know about the possibilities of enrolling lung cancer patients on clinical trials with three potentially highly active new chemotherapies.
- There is a practice gap that exists between conducting and not conducting Spiral CT scanning in heavy ex-smokers or current smokers versus only conducting conventional chest X-Rays. This practice will, no doubt, become more clearly defined prior to the September 2011 symposium, the subject of this grant request.
- There is a practice gap between which lung cancer trials are not known by and available to the community-based oncologists and those that are available for their patients that fail to respond to conventional therapies and are often ideal for their patients to benefit from such clinical trials.
|
|
|
|
|
|
This activity is designed to meet the educational needs of, and help close Practice Gaps of medical oncologists, hematologist/oncologists, radiation oncologists, surgical oncologists, pathologists, and other allied health-care professionals involved in the treatment, care and management of patients with lung cancer, including physician assistants, nurse practitioners/nurses, pharmacists, and fellows. Lung cancer is treated optimally by a multi-disciplinary approach of clinicians and, thus, all of the aforementioned clinician specialties are targeted for invitation.
|
|
|
|
|
Based on the data identified in the Needs Assessment and Physician Practice Gap Identification, the following Learning Objectives have been developed for these CME activities:
- Review the new predictive and prognostic NSCLC biomarker testing guidelines of the College of American Pathologists and the International Association for the Study of Lung Cancer (CAP/IASLC).
- Employ the new and evolving NSCLC algorithms.
- Order EGFR mutation test data for all eligible NSCLC patients.
- Utilize histology data for improving NSCLC outcomes.
- Explain the recent data regarding the optimal combination of radiation therapy and systemic therapy for NSCLC patients.
- Evaluate the eligibility of nonsquamous NSCLC patients for targeting angiogenesis.
- Describe the evidence-based strategies for retargeting EGFR in NSCLC patients who relapse.
- Differentiate the risks and benefits of novel and emerging chemotherapy strategies for lung cancer.
- Review the recent data regarding Spiral CT scans for identifying persons at high-risk for developing NSCLC.
- Describe the opportunities for enrolling NSCLC patients in clinical trials with emerging targets and novel strategies.
|
|
|
|
|
Based on the data identified in the Needs Assessment and Physician Practice Gap Identification, the following Learning Objectives have been developed for these CME activities:
- Recognize the new predictive and prognostic NSCLC biomarker testing guidelines of the College of American Pathologists and the International Association for the Study of Lung Cancer (CAP/IASLC).
- Recall the new and evolving NSCLC diagnostic and treatment algorithms.
- Define the EGFR mutation testing procedures for eligible NSCLC patients.
- Recognize how histology data improves NSCLC outcomes.
- Reproduce the recent data regarding the optimal combination of radiation therapy and systemic therapy for NSCLC patients.
- State the eligibility of nonsquamous NSCLC patients for targeting angiogenesis.
- Define the evidence-based strategies for retargeting EGFR in NSCLC patients who relapse following initial therapy.
- Recognize the risks and benefits of novel and emerging chemotherapy strategies for lung cancer.
- Recall the recent data regarding the risks and benefits of Spiral CT scans for identifying persons at high-risk for developing NSCLC.
- State the opportunities for enrolling NSCLC patients in clinical trials with emerging targets and novel strategies.
|
|
|
|
 The Biomedical Learning Institute is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The Biomedical Learning Institute designates this live activity for a maximum of 9 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
 The Biomedical Learning Institute is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
UAN: 0838-0000-11-001-L01-P
Credits: 7.5 hours (0.75 ceu)
Type of Activity: Knowledge
Physician Assistants: AAPA accepts certificates of attendance for educational activities certified for Category 1 credit from AOACCME, Prescribed credit from AAFP, and AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. Physician Assistants may receive a maximum of 9 hours of Category 1 credit for attending this symposium.
Nurse Practitioners, nurses, and Fellows will receive a certificate of attendance that they can submit to their accrediting organizations for continuing education credit.
|
|
|
|
|
There is an opportunity to exhibit at this symposium. Please send an email to phillip.renner@bmli.com for more information or call 214-269-2014.
|
|
| DISCLOSURE STATEMENT AND RESOLUTION OF ANY CONFLICTS OF INTEREST |
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, all educational programs sponsored by the Biomedical Learning Institute (BMLI) demonstrate fair balance, complete independence from any commercial supporters, objectivity, and scientific rigor. All faculty, authors, editors, BMLI staff and planning committee members participating in an educational activity who are in control of content or in communication with faculty are required to disclose any relevant financial interest or other relationships with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in a BMLI educational activity. All disclosures will be made available to all activity participants prior to the conduct of its educational activity. In addition, all conflicts of interest will be resolved prior to the conduct of its educational activity.
|
| DISCLOSURE OF UNLABELED USE |
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Biomedical Learning Institute does not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the Biomedical Learning Institute. Please refer to the official prescribing information for each product for discussion of approved indicated, contraindications, and warnings. |
| DISCLAIMER |
Participants of BMLI's educational activities have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development and practices. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities. |
|
|
